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Here we have designed a novel class of engineered antibody-based reagents (‘Seldegs’) that
induce the selective degradation of antigen-specific antibodies. We demonstrate the rapid
and specific clearance of antibodies recognizing the autoantigen, myelin oligodendrocyte
glycoprotein and tumour target, HER2. Seldegs have considerable potential in multiple areas,
including the treatment of antibody-mediated autoimmunity and diagnostic imaging.
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T
he development of strategies to specifically decrease
antigen-specific antibody levels for the clearance of
deleterious antibodies during therapy and diagnosis
represents a longstanding and unresolved challenge. Such an
approach would have broad utility in areas such as the treatment
of antibody-mediated autoimmunity, antibody-mediated trans-
plant rejection and the clearance of background during diagnostic
imaging. The knowledge that the neonatal Fc receptor, FcRn,
maintains immunoglobulin G (IgG) levels and transport in the
body has prompted the development of antibody- or peptide-
based inhibitors to reduce IgG levels1–5. However, these
inhibitors block the interaction of the Fc region of IgG with
FcRn and decrease levels of IgGs of all specificities, including
protective antibodies. To overcome these off-target effects, here
we have designed a novel class of engineered antibodies that
selectively clear antigen-specific antibodies without modulating
the levels of antibodies of other specificities. We have named
these agents ‘Seldegs’ to indicate their ability to selectively
degrade antibodies of defined specificities.
The design of clearing agents for antigen-specific antibodies
presents several challenges: first, antigen-specific antibody levels
are typically very low compared with those of antibodies of
irrelevant specificities, and these two antibody pools are similar
with shared constant regions but distinct variable domains.
Second, since the antibodies being targeted are bivalent, cross-
linking could result in inflammatory immune complexes. Seldegs
were therefore designed to display recombinant antigen as a
monomer linked to a dimeric, human IgG1-derived Fc fragment
using a similar approach to that described previously for
monomeric erythropoietin (Epo)-Fc fusions6. Mutations to
ablate interactions with human FcgRs7 and enhance binding to
FcRn in the pH range 6.0–7.4 (ref. 1) were inserted. Naturally
occurring IgGs have substantially higher affinity for FcRn at
acidic pH than at near neutral pH, and this property is essential
for the recycling and transcytosis of IgG within FcRn-expressing
cells8. By contrast, gain of binding affinity of an Fc (or IgG) for
FcRn at pH 7.4 results in receptor-mediated internalization into
cells and lysosomal delivery1,9,10. In the current study, we
demonstrate that Fc-antigen fusions, or Seldegs, containing such
affinity-enhanced Fc fragments selectively capture antigen-
specific antibodies and direct them into degradative lysosomal
compartments in FcRn-expressing cells.
Results
Clearance of antigen-specific antibodies by Seldegs. To
demonstrate the generality of the Seldeg approach, antibodies
specific for two antigens were targeted (Fig. 1a): first, the extra-
cellular domain (ECD) of myelin oligodendrocyte glycoprotein
(MOG-Seldeg), which is recognized by autoreactive antibodies in
both animal models of multiple sclerosis and multiple sclerosis in
humans11–13. Second, the ECD of HER2 (HER2-Seldeg), a well-
defined target for therapy and diagnostic imaging of HER2-
overexpressing tumours with HER2-specific antibodies such as
trastuzumab (TZB)14. Both MOG- and HER2-Seldegs have the
expected binding properties for FcRn, MOG-specific antibody
(8-18C5 (ref. 15)) and TZB (Fig. 1b; Supplementary Fig. 1;
Supplementary Table 1). The expression yields of the Seldegs are
B50mg l 1 (MOG-Seldeg) and B15mg l 1 (HER2-Seldeg).
SDS–polyacrylamide gel electrophoresis and high-performance
liquid chromatography analyses also indicate that these Fc fusion
proteins have favourable biophysical properties following storage
at 4 C (30 days) or 37 C (5 days) in PBS or human serum
(Supplementary Fig. 2). In addition, the Seldegs retain their
affinity for binding to 8-18C5 (KD¼ 33.0 nM; MOG-Seldeg) and
TZB (KD¼ 14.3 nM; HER2-Seldeg) following incubation for
5 days at 37 C.
We first investigated the ability of Seldegs to clear antigen-
specific antibodies in transgenic mice that express human FcgRs
(huFcgR mice)16. These mice were used since Seldegs have
human IgG1-derived Fc regions. Mice were injected with
125I-labelled, MOG-specific antibody 8-18C5 (ref. 15). Twenty-
four hours later, MOG-Seldeg was injected at a 16-fold (high
dose) or 4-fold (low dose) molar excess over target. The delivery
of MOG-Seldeg resulted in a rapid decrease in 8-18C5 levels in
the blood and whole body (Fig. 1c). Importantly, the total IgG
levels in serum of mice before and 48 h following treatment with
high or low dose of Seldeg were not significantly different
(Supplementary Fig. 3), indicating the selectivity of Seldeg-
mediated clearance. In addition, injection of an analogous
construct without the FcRn-enhancing MST-HN mutations
(MOG-WT) had no effect on 8-18C5 clearance (Fig. 1c).
To further analyse the specificity of Seldegs and their effect on
antibodies with different antigen recognition properties, the
behaviour of the HER2-specific humanized antibody TZB14 was
investigated in the presence of HER2-Seldeg and MOG-Seldeg
(Fig. 1d). HuFcgR mice were injected with 125I-labelled TZB and
subsequently with a 4-fold molar excess of Seldeg. As controls,
equivalent molar amounts of HER2-WT (analogous to HER2-
Seldeg without FcRn-enhancing mutations), MOG-Seldeg or hen
egg lysozyme-specific human IgG1 with the MST-HN mutations
(Abdeg)1 were used. This Abdeg contains the same mutations to
increase FcRn binding as those in the Seldegs. HER2-Seldeg
induced a decrease in TZB levels in the blood and whole body,
whereas the control proteins resulted in similar behaviour to that
observed for vehicle (PBS; Fig. 1d). Remarkably, blood levels of
TZB were reduced to B30% of the injected dose within 2 h
following Seldeg delivery (Fig. 1e).
Treatment with MOG- and HER2-Seldeg resulted in biphasic
clearance of the targeted radiolabelled antibodies (Fig. 1c,d).
Within the first B50 h of Seldeg delivery, the radiolabelled
antibodies are rapidly cleared. This is followed by slower
clearance rates that are close to those in control animals
(Fig. 1d). Analyses of the pharmacokinetic behaviour of
MOG- and HER2-Seldeg revealed relatively short b-phase half-
lives (MOG-Seldeg, 47.0±1.4 h (s.d.); HER2-Seldeg, 38.3±3.1 h;
n¼ 5 for both groups) that were similar to those of the Abdeg
(37.8±2.5 h; n¼ 5; Supplementary Fig. 4). For comparative
purposes, we also determined the b-phase half-lives of MOG- and
HER2-WT (102.3±22.0 and 87.2±11.9 h, respectively; n¼ 5 for
both groups). The rapid clearance of Seldegs is consistent with
earlier studies demonstrating that engineered antibodies with
increased binding to FcRn at near neutral pH results in shorter
in vivo half-lives8,17,18. This behaviour indicates that the
persistence of a low percentage of 8-18C5 or TZB following
B50 h of treatment is due to reduced levels of Seldeg, resulting in
incomplete capture of the targeted antibodies.
Seldegs internalize targeted antibodies into lysosomes. To
investigate the mechanism of Seldeg activity at the cellular level,
we analysed their effects on the internalization and accumulation
of 8-18C5 and TZB in endothelial cells (HMEC-1, human
microvasculature endothelial cells) transfected with a human
FcRn-GFP expression construct (mutated to confer binding
properties analogous to those of mouse FcRn19). Seldegs
efficiently internalize cognate antibodies into endosomes within
cells (Fig. 2a–c). Importantly, high levels of 8-18C5 or TZB in
cells result from treatment with MOG- or HER2-Seldeg,
respectively, and the majority of targeted antibody is retained
by the cells during a 60min chase (Fig. 2a). By contrast, target
antibody accumulation within cells is substantially lower in the
presence of MOG-WT (8-18C5) or HER2-WT (TZB), and the
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internalized antibody is efficiently recycled over 60min (Fig. 2a).
Following 8 h incubation, the targeted antibody and
corresponding Seldeg are delivered to lysosomes (Fig. 2d;
Supplementary Fig. 5). Importantly, cells do not accumulate
8-18C5 and TZB in lysosomes in the presence of HER2-Seldeg or
MOG-Seldeg, respectively (Fig. 2d; Supplementary Fig. 5).
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In summary, we have demonstrated that engineered antigen-Fc
fusion proteins (Seldegs) induce rapid and substantial decreases
of antigen-specific antibody levels. Further, Seldegs are effective at
relatively low doses that, by contrast with earlier approaches1–5,
do not alter the clearance of antibodies of non-targeted
specificities. The properties of Seldegs indicate their potential
applications in multiple clinical situations where it is desirable to
selectively clear antibodies of defined specificities.
Methods
Cell lines. HMEC-1 cells, a generous gift from Francisco Candal (CDC), were
maintained in phenol red-free HAMS F12-K medium (US Biological). BT-474
(American Type Culture Collection; HTB-20) were maintained according to the
supplier’s protocol. Cell lines were tested at monthly intervals for mycoplasma
contamination and were authenticated by short tandem repeat analysis.
Generation of expression constructs. The gene encoding the HER2 leader
peptide and ECD (consisting of 629 residues) was isolated from a HER2-over-
expressing breast cancer cell line (BT-474) employing standard molecular biology
techniques. This gene was fused via a IEGRMD linker peptide to the N terminus of
the hinge region of a gene encoding the human IgG1-derived Fc fragment using
splicing by overlap extension20. Mutations to ablate binding to FcgRs (G236R/
L328R; EU numbering)7, enhance binding to FcRn (MST-HN; M252Y/S254T/
T256E/H433K/N434F)1 and generate ‘knobs-into-holes’ (Y349T/T394F)21,22 were
inserted into the Fc fragment gene using standard methods. Cysteine (C220) in the
hinge region that bridges with cysteine in the light-chain constant region was also
mutated to serine. Fc fragment genes without fused antigen were generated with
complementary knobs-into-holes mutations (S364H/F405A)21,22. Similar
methodology as described above was used to produce a fusion construct encoding
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Figure 2 | Seldegs increase the accumulation of antigen-specific antibodies in human endothelial (HMEC-1) cells expressing FcRn-GFP. (a) HMEC-1
cells were incubated with 100 nM Alexa 647-labelled 8-18C5 (MOG-specific) or TZB (HER2-specific) in complex with 400nM MOG-Seldeg/MOG-WTor
HER2-Seldeg/HER2-WT for 30min and chased for 0 (30’ P) or 60min (30’ P, 60’ C). Mean fluorescence intensities (MFI) of Alexa 647-labelled 8-18C5 or
TZB for triplicate samples were determined by flow cytometry. Error bars indicate s.d. (b,c) HMEC-1 cells were plated on coverslips and treated as in a,
except that Seldegs or control WTproteins were labelled with Alexa 555 and cells were fixed for microscopy. Images of representative cells from multiple
cells analysed are shown with GFP, Alexa 555 and Alexa 647 in overlays pseudocoloured green, red and blue, respectively. Representative endosomes in
the insets are cropped and expanded. (d) HMEC-1 cells were pre-pulsed with Alexa 555-labelled dextran for 2 h, washed and pulsed with 8-18C5 in
complex with MOG-Seldeg, MOG-WTand HER2-Seldeg (concentrations and labels as for a) for 30min, followed by an 8 h chase. Cells were washed, fixed
and imaged, and images for a representative cell from multiple cells analysed are presented. Representative lysosomes in the insets are cropped and
expanded. For the overlay, GFP, Alexa 555 and Alexa 647 are pseudocoloured as in b. For b–d, scale bars¼ 5 mm, and for insets, scale bars¼0.25mm. Data
shown are representative of at least two independent experiments.
Figure 1 | TZB and 8-18C5 are rapidly cleared by Seldegs in transgenic mice expressing huFccRs. (a) Schematic representation of Seldeg design.
(b) A concentration of 100 nM MOG-Seldeg or MOG-WT was injected over immobilized mouse FcRn at the indicated pH. (c) Mice were intravenously
injected with radiolabelled (125I) 8-18C5 (15mg) and 24h later PBS, MOG-WT (31 mg) or MOG-Seldeg (4-fold (31mg) or 16-fold (125mg) molar excess; low
or high dose, respectively) was delivered intravenously. Radioactivity levels were determined at the indicated times. Whole body or blood levels obtained
immediately before Seldeg or control delivery were taken as 100%. (d,e) The same methodology as in c was used, except that radiolabelled TZB (15mg)
injection was followed 24 h later by intravenous delivery of PBS, HER2-WT (51mg), HER2-Seldeg (51mg), MOG-Seldeg (31 mg) or Abdeg (MST-HN; 60mg),
each at fourfold molar excess. Error bars indicate s.d. and statistically significant differences are indicated for MOG-WT versus MOG-Seldeg (low)
(c) HER2-Seldeg versus MOG-Seldeg (d) and HER2-Seldeg versus Abdeg (e) by *(Po0.05, two-way analysis of variance with Tukey’s multiple
comparisons; n¼ 6 mice per group). Data shown are representative of two independent experiments.
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the ECD of mouse MOG23 linked to the same engineered Fc fragment, using a
GGGGS linker. Analogous (‘wild type’) expression constructs were also made to
express antigen-Fc fusions without the MST-HN mutations. Sequences of the
expression constructs are available upon request.
Protein expression and purification. Recombinant proteins were expressed in
HEK-293F (Life Technologies) cells following transient transfection with the Gibco
Expi293 expression system kit (Life Technologies). The MST-HN mutations reduce
binding of the Fc region to protein G-Sepharose and Seldegs were therefore
purified using an anion exchange column (SOURCE-15Q, GE Healthcare) at
pH 8.0 and a linear salt gradient (0–0.5M NaCl). HER2-WT and MOG-WT were
purified using protein G-Sepharose (GE Healthcare). 8-18C5 was expressed in
recombinant form and purified using protein G-Sepharose23, and clinical grade
TZB (Herceptin; Roche) was obtained from the UT Southwestern Medical Center
Pharmacy. Recombinant Abdeg (MST-HN, hen egg lysozyme-specific) was purified
from culture supernatants using lysozyme-Sepharose1. All recombinant proteins
were purified using size-exclusion chromatography (GE Healthcare) in PBS
(Lonza) before use in experiments.
Analyses of Seldeg stability. For serum stability assays, endogenous IgGs were
depleted from human male AB plasma (Sigma) by passage through protein
G-Sepharose (GE Healthcare). Seldegs were incubated in serum at a concentration
of 100 nM at 37 C for 3 or 5 days. Following incubation, Seldegs were immuno-
precipitated using agarose beads coupled to goat anti-human Fc-specific antibody
(Sigma). Immunoprecipitated Seldegs were run on 12% SDS–polyacrylamide gels,
transferred to polyvinylidene difluoride membranes (Millipore) and membranes
incubated with horseradish peroxidase-conjugated goat anti-human Fc-specific
(Hþ L) antibody (Jackson ImmunoResearch). Bound secondary conjugate was
detected using Westernsure substrate, followed by scanning with a C-DiGit blot
scanner (LI-COR).
Seldegs were also incubated in PBS (Lonza) at 4 C (30 days) or 37 C for 5 days,
followed by analyses using a Superdex 200 5/150 GL column (GE Healthcare),
12% SDS–polyacrylamide gel electrophoresis and surface plasmon resonance
(BIAcore).
Surface plasmon resonance analyses. Surface plasmon resonance experiments
were carried out using a BIAcore T200 (GE Healthcare). To determine the equi-
librium binding affinities for the interactions of Seldeg/WT proteins with anti-
bodies (8-18C5 or TZB), 8-18C5 or TZB were injected over immobilized Seldeg/
WT proteins (coupled atB350–2,000 relative units on flow cells of CM5 sensor
chips) at a flow rate of 10ml min 1 in PBS (Lonza; pH 7.4) plus 0.01% v/v Tween-20.
Flow cells were regenerated at the end of each run using 0.15M NaCl and 0.1M
glycine (pH 2.3). The equilibrium dissociation constants (KDS) for the interactions of
Seldegs/WT with TZB or 8-18C5 were determined using a 1:1 interaction model and
custom-written software24. Binding of Seldeg/WT to recombinant human or mouse
FcRn in PBS (pH 6.0 or 7.4) plus 0.01% v/v Tween-20 was analysed by injecting
100nM Seldeg/WT over immobilized FcRn (coupled at B600 relative units on a
CM5 sensor chip) at a flow rate of 10mlmin 1 (ref. 19). The flow cells were
regenerated using 0.15M NaCl and 0.1M sodium bicarbonate (pH 8.5).
Antibody labelling. 8-18C5, TZB, Seldeg, corresponding WT fusion proteins and
MST-HN Abdeg were radiolabelled with 125I using Iodogen (Perkin Elmer or MP
Biomedicals)25. 8-18C5 and TZB were fluorescently labelled with Alexa 647 Fluor
(ThermoFisher Scientific) with antibody:dye ratios of 1.6 and 3, respectively.
Seldeg/WT fusion proteins were fluorescently labelled with Alexa 555 Fluor
(ThermoFisher Scientific) dye at a protein:dye ratio of 2.7 (MOG-WT), 2.5
(MOG-Seldeg), 1.5 (HER2-WT) and 1.2 (HER2-Seldeg) using the manufacturer’s
protocol.
Fluorescence microscopy and recycling assay. HMEC-1 cells were transiently
co-transfected using Nucleofector technology (Lonza) with human FcRn-GFP
(FcRn tagged at the C terminus with GFP) and human b2 microglobulin26. FcRn-
GFP containing, a mutated version of human FcRn with similar binding properties
as mouse FcRn19, was used throughout these studies.
For microscopy studies, FcRn-GFP-transfected cells were plated in IgG-
depleted phenol red-free HAMS F-12K medium on micro-coverglasses
(Electron Microscopy Sciences). Eighteen hours post transfection, cells were pulsed
with labelled antibodies at a 1:4 molar ratio of 8-18C5 or TZB (15 mgml 1) to
MOG- or HER2-Seldeg/WT (31 and 51 mgml 1 for MOG- and HER2-Seldeg/WT,
respectively) for 30min. This pulse was followed by two washes with ice-cold PBS
and fixation with 1.7% (w/v) paraformaldehyde (Electron Microscopy Sciences)
with 0.025% (v/v) glutaraldehyde (Sigma) on ice for 10min. Alternatively,
following the 30min pulse, cells were washed with PBS and chased in medium for
60min before further washes and fixation. To label lysosomes, transfected cells
were pre-pulsed with Alexa 555-labelled dextran (ThermoFisher Scientific;
500mgml 1) for 2 h, followed by pulsing with labelled antibodies (as above) for
30min and a chase period of 8 h. All pulse-chase experiments were carried out in
phenol red-free HAMS F-12K medium (pH 7.4) at 37 C in a 5% CO2 incubator.
Fixed cells were imaged with a Zeiss Axiovert 200M inverted microscope, and
acquired data were analysed using in-house written software (MIATool
26
). For
recycling assays, transfected HMEC-1 cells were plated in 24-well plates at a density
of 50,000 cells per well. Eighteen hours post transfection, cells were pulsed with
medium containing labelled antibodies as for the microscopy experiments. At the
end of the chase period, cells were washed with ice-cold PBS, followed by
trypsinization (PBS and trypsin were maintained at pH 6.0). Trypsinized cells were
collected, fixed on ice for 5min with 1.7% paraformaldehyde (w/v) and analysed
using a LSRFortessa flow cytometer (BD Biosciences). Flow cytometry data were
analysed using Flowjo (FlowJo).
Studies in mice. All pharmacokinetic experiments were carried out in 8–10-week-
old male or female C57BL/6 mice that transgenically express human FcgRs16.
Animals were housed in a pathogen-free facility at Texas A&M University and all
animal experiments were approved by the Texas A&M Institutional Animal Care
and Use Committee. Mice were injected intravenously with 15 mg radiolabelled
antibody (8-18C5 or TZB) in 200 ml 0.1% BSA in PBS (Lonza). Twenty-four hours
later, Seldegs and controls (n¼ 6 mice per group) were intravenously delivered in
200 ml PBS at a 4-fold or 16-fold molar excess as indicated in the figure legends.
Whole-body radioactive counts were obtained using an Atom Lab 100 dose
calibrator (Biodex). Mice were retroorbitally bled using 10 ml capillary tubes
(Drummond) and radioactive counts (c.p.m.) obtained by gamma counting
(Perkin Elmer). To determine total serum IgG levels, mice were retroorbitally bled
with 44.7 ml heparinized capillary tubes (VWR International) and IgG
concentrations in 1:25,000 dilutions of serum in PBS quantified by enzyme-linked
immunosorbent assay1. All radioactive counts were expressed as the percentage of
the levels obtained from serum samples and whole-body counting immediately
before Seldeg/control delivery.
To determine the b-phase half-lives of MOG-WT or -Seldeg, HER2-WT or
-Seldeg, and Abdeg (MST-HN), radiolabelled WT/Seldeg or Abdeg were injected
(n¼ 5 mice per group) at a dose per mouse of 20 mg radiolabelled protein and 10,
31 and 40mg of unlabelled proteins for MOG-WT or
-Seldeg, HER2-WT or -Seldeg, and Abdeg, respectively. The b-phase half-lives for
the proteins were determined by fitting the data to a biexponential model25.
Statistical analyses. Statistical analyses was carried in GraphPad Prism
(GraphPad Software, Inc.) by two-way analysis of variance with Tukey’s multiple
comparison test.
Data availability. All relevant data and sequences of constructs used in this study
are available on request.
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